Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 2:: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes

被引：72
|
作者：
Finke, PE
Meurer, LC
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
机构：
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 02期
关键词：
D O I：
10.1016/S0960-894X(00)00639-9
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2,3-dihydrobenzthiophene-3,4'-piperidin-1'-yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16. X=H, 3-F, 3-Cl, 3-Me). (C) 2001 Published by Elsevier Science Ltd.
引用
收藏
页码：265 / 270
页数：6
相关论文
共 50 条
  • [1] Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 4:: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
    Finke, PE
    Oates, B
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Gould, SL
    DeMartino, JA
    Carella, A
    Carver, G
    Holmes, K
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2475 - 2479
  • [2] Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 3:: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)4-[4-(substituted)piperidin-1yl]butanes
    Finke, PE
    Meurer, LC
    Oates, B
    Shah, SK
    Loebach, JL
    Mills, SG
    MacCoss, M
    Castonguay, L
    Malkowitz, L
    Springer, MS
    Gould, SL
    DeMartino, JA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2469 - 2473
  • [3] Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
    Dorn, CP
    Finke, PE
    Oates, B
    Budhu, RJ
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Daugherty, BL
    Gould, SL
    DeMartino, JA
    Siciliano, SJ
    Carella, A
    Carver, G
    Holmes, K
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) : 259 - 264
  • [4] Investigation of Structure-Activity Relationship Between Chemical Structure and CCR5 Anti HIV-1 Activity in a Class of 1-[N-(Methyl)-N- (Phenylsulfonyl) Amino]-2-(Phenyl)-4-[4-(Substituted)Piperidin-1-yl]Butane Derivatives: The Electronic-Topological Approach
    Saracoglu, Murat
    Kandemirli, Sedat Giray
    Basaran, Murat Alper
    Sayiner, Hakan
    Kandemirli, Fatma
    CURRENT HIV RESEARCH, 2011, 9 (05) : 300 - 312
  • [5] CCR5 antagonists as anti-HIV-1 agents.: Part 2:: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N′-diphenylureas
    Imamura, S
    Kurasawa, O
    Nara, Y
    Ichikawa, T
    Nishikawa, Y
    Iida, T
    Hashiguchia, S
    Kanzaki, N
    Iizawa, Y
    Baba, M
    Sugihara, Y
    BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (09) : 2295 - 2306
  • [6] N-[4-(4-Bromophenyl)thiazol-2-yl]4-(piperidin-1-yl)butanamide
    Ghabbour, Hazem A.
    Kadi, Adnan A.
    EI-Subbagh, Hussein I.
    Chia, Tze Shyang
    Fun, Hoong-Kun
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2012, 68 : O1665 - +
  • [7] Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor
    Xu, Y
    Liu, H
    Niu, CY
    Luo, C
    Luo, XM
    Shen, JH
    Chen, KX
    Jiang, HL
    BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (23) : 6193 - 6208
  • [8] Synthesis and evaluation of CCR5 antagonists containing modified 4-(piperidin-1-yl)-2-phenyl-1-(phenylsulfonylamino)-butane.
    Shah, SK
    Chen, N
    Guthikonda, RN
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Gould, SL
    DeMartino, JA
    Carella, A
    Carver, G
    Holmes, K
    Schleif, WA
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Emini, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U657 - U657
  • [9] CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives
    Imamura, S
    Nishikawa, Y
    Ichikawa, T
    Hattori, T
    Matsushita, Y
    Hashiguchi, S
    Kanzaki, N
    Iizawa, Y
    Baba, M
    Sugihara, Y
    BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (02) : 397 - 416
  • [10] Structure -: Activity relationship study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents.: 2
    Leopoldo, Marcello
    Lacivita, Enza
    Contino, Marialessandra
    Colabufo, Nicola A.
    Berardi, Francesco
    Perrone, Roberto
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (17) : 4214 - 4221
12345